Published in Oncotarget on March 15, 2016
Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer (MITO16MANGO2b) | NCT01802749
Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation. Oncotarget (2016) 0.75
Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials. Oncotarget (2016) 0.75
Ovarian function following targeted anti-angiogenic therapy with bevacizumab. Mol Clin Oncol (2017) 0.75
Measuring inconsistency in meta-analyses. BMJ (2003) 128.20
Bias in meta-analysis detected by a simple, graphical test. BMJ (1997) 122.24
Operating characteristics of a rank correlation test for publication bias. Biometrics (1994) 47.97
Practical methods for incorporating summary time-to-event data into meta-analysis. Trials (2007) 14.51
Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med (2011) 8.93
A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med (2011) 8.63
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol (2014) 6.28
Progression-free survival: meaningful or simply measurable? J Clin Oncol (2012) 2.83
Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol (2014) 1.69
Bevacizumab in the treatment of ovarian cancer: a meta-analysis from four phase III randomized controlled trials. Arch Gynecol Obstet (2013) 0.99
Phase III trials of standard chemotherapy with or without bevacizumab for ovarian cancer: a meta-analysis. PLoS One (2013) 0.98